Operations Research of the 'Real World' Effectiveness of Multi-Month Dispensing of ART for Stable Patients in CARGs in Zimbabwe
NCT03238846 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4676
Last updated 2018-10-17
Summary
This study aims to evaluate the effectiveness of two strategies for multi-month dispensing (MMD) of ART in Community ART Refill Groups (CARGs) on retention, virologic suppression, and cost compared to standard of care.
This study is a three-arm cluster-randomized controlled trial conducted among 5,760 stable HIV-positive patients) in Zimbabwe to compare outcomes of three antiretroviral therapy (ART) dispensing models. Outcomes of retention in care, virologic suppression, and cost effectiveness will be investigated in 30 purposively selected clusters (facilities) which are randomized into three arms; standard of care (3 months dispensing at facilities), three-month dispensing in CARGs, and six-month dispensing in CARGs. Each study arm will have 10 clusters stratified into 2 urban and 8 rural. Study participants will be followed, and outcomes will be measured at 12 months and 24 months. Qualitative research will be conducted at baseline, 12 months, and 24 months (20 participant Focus Group Discussion (FGDs) and 20 provider Key Informant Interview (KII) at each interval) to understand patient and health provider acceptability of multi-month dispensing of ART within CARGs. Other outcomes of interest include measuring gains of facility decongestion and feasibility of multi-month dispensing of ART within CARGs. Cost analysis will include comparisons of patient level costs, cost per patient outcomes and cost effectiveness across the three study arms.
Conditions
Interventions
- OTHER
-
Three month dispensing of ART in CARGs
Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
- OTHER
-
Six month dispensing of ART in CARGs
Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
Sponsors & Collaborators
-
Ministry of Health and Child Welfare, Zimbabwe
collaborator OTHER -
EQUIP Innovation for Health
collaborator UNKNOWN -
Organization for Public Health Interventions and Development (OPHID)
collaborator UNKNOWN -
Family Health International (FHI 360)
collaborator UNKNOWN -
Population Services International (PSI)
collaborator UNKNOWN -
Kheth'Impilo
lead OTHER
Principal Investigators
-
Nicoletta Ngorima-Mabhena, MBChB, MSc Epidemiology · Kheth'Impilo
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-28
- Primary Completion
- 2019-09-30
- Completion
- 2019-09-30
Countries
- Zimbabwe
Study Locations
More Related Trials
-
Comparison of Facility and Home-based ART Delivery Systems in Uganda
NCT00144365 ·Status: COMPLETED ·Phase: PHASE3
-
Community-Based Model for Delivery of Antiretroviral Therapy in Cambodia
NCT04766710 ·Status: RECRUITING ·Phase: NA
-
Delivery Optimization for Antiretroviral Therapy (The DO ART Study)
NCT02929992 ·Status: COMPLETED ·Phase: NA
-
Differentiated Care for Improved Health Systems Efficiency and Health Outcomes in Zambia
NCT02776254 ·Status: COMPLETED ·Phase: NA
-
Modified Directly Observed Antiretroviral Therapy
NCT01985269 ·Status: UNKNOWN ·Phase: NA
-
Examining HIV Treatment Adherence During Early Disease
NCT02419066 ·Status: COMPLETED
-
Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women
NCT03282799 ·Status: COMPLETED ·Phase: PHASE2
-
Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa
NCT06133686 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Strategic Antiretroviral Therapy and HIV Testing for Youth in Rural Africa
NCT03848728 ·Status: COMPLETED ·Phase: NA
-
Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis
NCT00976040 ·Status: COMPLETED ·Phase: PHASE4
-
The Impact of Home Delivery of Antiretroviral Therapy on Virological Suppression
NCT02711293 ·Status: COMPLETED ·Phase: NA
-
Early HIV Therapy in Patients With High CD4 Cell Counts
NCT01479634 ·Status: COMPLETED ·Phase: NA
-
Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals
NCT03723525 ·Status: COMPLETED ·Phase: PHASE4
-
HeadStART: Evaluating the Effectiveness of Community ART Delivery for People Newly Diagnosed With HIV
NCT06126913 ·Status: RECRUITING ·Phase: NA
-
Rudi Kundini, Pamoja Kundini: Phase I
NCT05248100 ·Status: COMPLETED ·Phase: NA
-
A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy
NCT02082652 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients
NCT00398996 ·Status: COMPLETED ·Phase: PHASE3
-
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
NCT00663234 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART
NCT01751646 ·Status: COMPLETED ·Phase: NA
-
Pre-ART Retention in Care in Tanzania
NCT01992887 ·Status: COMPLETED
-
Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings
NCT00091936 ·Status: COMPLETED ·Phase: NA
-
International HIV Antiretroviral Adherence, Resistance and Survival
NCT01596322 ·Status: COMPLETED
-
Immune Reconstitution in HIV Disease (IREHIV)
NCT01702974 ·Status: COMPLETED ·Phase: PHASE2
-
Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment
NCT00737724 ·Status: TERMINATED ·Phase: NA
-
PathToScale: An Implementation Evaluation
NCT06319105 ·Status: RECRUITING